| INTRODUCTION
Variceal haemorrhage represents a severe complication of portal hypertension in patients with liver cirrhosis. Despite improvements in the management of acute variceal haemorrhage, bleeding-related mortality remains as high as 15%-20%. [1] [2] [3] [4] Current guidelines recommend either non-selective b-blockers (NSBBs) or endoscopic band ligation (EBL) for primary prophylaxis of variceal bleeding. 5 Traditionally, propranolol or nadolol have been used for prophylaxis of variceal haemorrhage. [6] [7] [8] [9] More recently Carvedilol has emerged as a new alternative NSBB with additional antia1 adrenergic activity resulting in greater efficacy for decreasing portal pressure and superior haemodynamic response rates. [10] [11] [12] [13] In a cochrane analysis comparing NSBBs and EBL for primary prophylaxis, 14 patients who underwent EBL showed a reduction in upper gastrointestinal and variceal bleeding eposiodes compared with NSBB. Another meta-analysis also showed a superior efficacy of EBL over NSBBs for primary prophylaxis especially in high-risk oesophageal varices. 15 A randomised study using the NSBB carvedilol showed better efficacy for primary prophylaxis compared to EBL, 16 while this was questioned in another multicentre trial. 17 Although bleeding rates varied between different studies in primary prophylaxis, no difference between the overall effectiveness, and overall-or bleeding-related mortality were noted between EBL and NSBB treatment groups in primary prophylaxis. 14, 16, [18] [19] [20] [21] Secondary prophylaxis is the prevention of recurrent variceal haemorrhage, which has a major impact on mortality. 22, 23 The
Baveno guidelines recommend the combination of EBL and NSBBs (EBL + NSBB) for secondary prophylaxis of variceal bleeding. 5 This combination is more effective to prevent recurrent variceal haemorrhage than the respective monotherapies with EBL or NSBBs alone. [24] [25] [26] [27] [28] In an updated individual patient meta-analysis presented at the Baveno VI consensus conference, it was suggested that the addition of NSBB to EBL does also improve survival in secondary
prophylaxis.
Here, we report our real-life experience on the efficacy of EBL for primary and secondary prophylaxis for variceal bleeding at two large tertiary centres in Vienna.
| PATIENTS AND METHODS

| Study design
This study was designed as a retrospective two centre study includ- and June/2015 were identified and considered for this retrospective study. Inclusion criteria were the presence of oesophageal varices at endoscopy, age >18 years and the diagnosis of liver cirrhosis.
Patients with non-cirrhotic portal hypertension receiving endoscopic treatment other than EBL, previous transjugular intrahepatic portosystemic shunt (TIPS) implantation or orthotopic liver transplantation (OLT), or insufficient medical/endoscopic records were excluded from this study. The primary endpoints were (re-)bleeding rates and transplant-free survival. We compared patients undergoing EBL for primary and secondary prophylaxis of variceal bleeding with or without concomitant NSBB treatment. To compare EBL and EBL + NSBB therapy with NSBB monotherapy in primary prophylaxis we used patient data from two previous studies. 10, 29 The decision to use EBL monotherapy, or the combination of NSBBs and EBL was based on the treating physicians' discretion.
| Parameters
Clinical, laboratory and endoscopic parameters, as well as data on the clinical outcomes (variceal bleeding, TIPS implantation, death, acute or chronic liver failure and decompensating events) were recorded. All patients were followed until death or last clinical visit.
Number of endoscopies, EBL treatments, laboratory parameters, con- were analysed by Kaplan-Meier curves and group comparisons were performed using log-rank test. Multivariable Cox proportional hazards regression models were used to test the independent association between NSBB treatment and survival or rebleeding in primary and secondary prophylaxis. Competing risk Cox regression analysis was used according to the method of Fine and Gray to provide particular events including death, transplantation, bleeding or decompensated event, generated by the proportional subdistribution hazards model. Propensity score matching was performed to reduce the selection bias due to confounding factors. All variables, which have a clinical relevance to the outcome of mortality and bleeding, were used. A P-value ≤0.05 was considered statistically significant.
| Ethics
This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of the Medical PFISTERER ET AL.
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University of Vienna (EK#1666/2015) and the ethics committee of the Krankenanstaltenverbund Vienna (MA-15, EK#15-280-VK).
3 | RESULTS
| Patient characteristics
Nine hundred and seventy patients, who underwent endoscopic banding ligation (EBL) were considered for this retrospective analysis. After exclusion of n = 204 patients meeting exclusion criteria, a total number of 766 patients were included.
Among the n = 284 patients undergoing sequential EBL for primary prophylaxis, n = 101 (35.6%) received EBL only, while n = 180 (63.4%) received EBL and concomitant NSBBs. Among the n = 482 patients treated with EBL for secondary prophylaxis, n = 163 (33.8%) received EBL only, while n = 299 (62.0%) received EBL + NSBB combination therapy.
Baseline characteristics of patients on primary prophylaxis and secondary prophylaxis are summarised in Table S1 . Serum albumin levels were significantly lower, INR was significantly higher, and gamma-glutamyltransferase (GGT) values were significantly elevated in secondary prophylaxis as compared to primary prophylaxis. In the setting of secondary prophylaxis, there were significantly more rebleedings (38.4% vs first bleedings: 16.2%, P<0.001) and more TIPS implantations (11.4% vs 4.6%, P = 0.001) than in primary prophylaxis ( Figure 1 ; Table S1 ). In primary prophylaxis, concomitant NSBB therapy did not impact on bleeding rates (9.9% vs 10% at year 1 (Y1), 16 .7% vs 13.3% at Y2, 19.7% vs 14.7% at Y3, log-rank P = 0.353) nor on mortality (27.8% vs 19.5% at Y1, 40.2% vs 31.7% at Y2, 44.6% vs 39.9% at Y3, log-rank P = 0.497) when compared to an EBL monotherapy strategy.
Compared to another group of patients receiving NSBB monotherapy in primary prophylaxis, incidence of first variceal bleeding was similar as compared to the EBL + NSBB and EBL-monotherapy group (EBL vs EBL + NSBB: log-rank P = 0.981, NSBB vs EBL + NSBB: log-rank P = 0.353).
In primary prophylaxis n = 36 (12.7%) patients bled for the first time during follow-up. No single parameter was associated with first variceal bleeding on univariate analysis. On multivariate analysis, considering age, sex, size of varices, aetiologies, MELD score, serum albumin, presence of severe/refractory ascites and use of NSBB, again no independent risk factor for bleeding was identified. Thus, the addition of NSBBs to EBL in primary prophylaxis did not improve bleeding control in primary prophylaxis (Table 1, Table 2 , Figure 2 ).
| Secondary prophylaxis
Patients in the EBL + NSBB group had slightly higher MELD and showed a higher proportion of patients with large varices (P = 0.029) and patients treated with EBL alone were older (age: In secondary prophylaxis, patients with EBL + NSBB combination therapy showed similar rebleeding rates as compared to EBL alone
T A B L E 2 Risk factors for first variceal bleeding in primary prophylaxis
No-Bleeders Figure 3 ).
| Reasons for non-use of non-selective betablockers in secondary prophylaxis
In total, n = 163 patients in secondary prophylaxis were treated with EBL monotherapy. Interestingly, 121 (74.2%) of them had unknown reasons for using only EBL and no specific contraindications were recorded in the medical history. Contraindications (mostly relative)
were present with COPD in n = 7 (4.3%), arterial hypotension in n = 27 (16.6%), haemodynamic non-response in n = 2 (1.2%), as well as diabetes, peripheral artery disease and AV-Block in n = 1 (2.5%)
respectively. Interestingly, intolerance to NSBB was reported in only n = 2 patients (1.2%) (Table S2 ). (Table 4) . Chi-square tests and Mann-Whitney U tests were performed to compare the respective proportions between patients on EBL vs EBL + NSBB in secondary prophylaxis.
| Mortality and causes of death in secondary prophylaxis
Overall, there were significantly more deaths during follow-up in patients on secondary prophylaxis who received only EBL monotherapy therapy (57.7%) than in patients treated with EBL + NSBB combination therapy for secondary prophylaxis (38.5%,
P<0.001).
Increased creatinine levels (OR: CI: 1.08-2.24, P = 0.017) were identified as independent risk factors for mortality.
Due to potential bias in patient characteristics, we also computed a propensity score considering potential risk factors for mortality. When the propensity score derived from gender, age, serum albumin levels, MELD, size of varices and presence of severe/refractory ascites was included into the regression model for survival, treatment modality of EBL + NSBB combination was not independently associated with survival. However, propensity score was a significant predictor of survival in secondary prophylaxis.
However, the significantly lower mortality in secondary prophylaxis observed in the EBL + NSBB combination therapy early after initiation of secondary prophylaxis prompted us to assess the causes of deaths in the first year of secondary prophylaxis when the survival curves were impressively separating. Indeed, most deaths in secondary prophylaxis were observed within the first year after baseline EBL (EBL: 76% vs EBL+NSBB: 39.1%, P<0.001). In the EBL + NSBB combination therapy group, significantly less deaths were attributed to liver-related events (ie, coma hepaticum, liver-failure and encephalopathy; 29.3% vs 14.8%, P = 0.011), bleeding-related deaths (18.5% vs 7.8%, P = 0.022) and infection/sepsis (10.9% vs 3.5%, P = 0.035) as compared to the EBL monotherapy.
However, no significant difference was found regarding 'other'
causes of death including multi-organ-failure, cardiovascular diseases, or respiratory failure (8.7% vs 10.4%, P = 0.674) and unknown causes of death (8.7% vs 2.6%, P = 0.052).
Thus, we computed multivariate analysis on the impact of NSBB treatment on early 6-months mortality in secondary prophylaxis.
Here, we could demonstrate that additional NSBB intake (HR: 0.53 Tables 5-6, Table S1 ).
| DISCUSSION
We assessed (re)bleeding and mortality rates using endoscopic band ligation (EBL) for primary and secondary prophylaxis in a large cohort of cirrhotic patients treated at two major liver units in a real-life setting.
Although Baveno VI guidelines do not recommend to use combined endoscopic band ligation and nonselective betablockers (EBL + NSBB) for primary prophylaxis, and do not recommend EBL alone for secondary prophylaxis, these strategies seem to be used in daily practice. In our study only 35.6% (n = 101 patients) received EBL only for primary prophylaxis, while 63.4% (n = 180 patients) received EBL + NSBB combination therapy. Thus, more than a half of patients receiving EBL for primary prophylaxis also received NSBBs.
For the setting of primary prophylaxis, we had the chance to included patients treated with NSBB monotherapy from two previous studies. 10, 29 First we could confirm that EBL + NSBB has no beneficial effect on first bleeding rates in primary prophylaxis both versus EBL alone or NSBB alone. There was also no difference between EBL monotherapy or EBL + NSBB combination therapy in secondary prophylaxis. However, we found superior survival in the NSBB monotherapy as compared to the EBL + NSBB group-which is most likely attributable to a selection bias with exclusively confirmed haemodynamic responders in the NSBB trials by Reiberger et al However, a recent trial showed that EBL + NSBB combination therapy was more effective in reducing the incidence of first variceal bleeding especially in high risk oesophageal varices than monotherapy with EBL with less recurrence of varices in the EBL + NSBB group than with EBL alone. 33 Ultimately, this strategy remains to be confirmed in future studies.
In secondary prophylaxis, 33.8% received EBL only and 62%
received EBL + NSBB combination therapy. Thus, one-third had no concomitant NSBB treatment-which would have been recommended by the Baveno guidelines. A total of 163 patients in (74.2%) of them had unknown reasons for using only EBL because no contraindication was mentioned in the history, while only a few patients had specific (but relative) contraindication to NSBB therapy.
However, considering that the Baveno IV Guidelines clearly recommended the combination of NSBB and EBL for secondary prophylaxis 34 the proportion of patients treated with EBL alone seems rather large.
While there was no significant effect of EBL + NSBB combination over EBL monotherapy in terms of preventing rebleeding, we found a significant survival benefit with NSBB + EBL combination therapy in secondary prophylaxis. The beneficial effect of additional NSBB therapy was most pronounced in the first 6-12 months after initiation of secondary prophylaxis. Since rebleeding rates were not substantially reduced with EBL + NSBB combination therapy, we assume that the observed survival benefit was most likely due to non-haemodynamic effects of NSBB treatment. 29, 35 Therefore, we next analysed the causes of death within the first year of secondary prophylaxis: In our study, secondary prophylaxis without NSBB (EBL only) was associated with an increased risk of liver-related deaths (29.3% vs 14.8%) and infections-related (10.9% vs 3.5%) death as compared to standard of care with EBL + NSBB combination therapy (10.9% vs 3.5%).
Various studies revealed that a reduction in the portal pressure with NSBB is also associated with a decreased risk of spontaneous bacterial peritonitis (SBP), [36] [37] [38] 37 and even reduces the mortality in patients who go on to develop acute-on-chronic liver failure is developed. 40 Other causes of death were not significantly different between EBL-monotherapy and EBL + NSBB combination therapy within the first year of secondary prophylaxis.
A recent meta-analysis based on single patient data showed that the NSBB therapy represents the most critical component of secondary prophylaxis. The study also showed an increased risk of rebleeding and death in patients treated with EBL alone compared to EBL + NSBB. 41 Interestingly, alcoholic aetiology was associated with a decreased risk of rebleeding vs other aetiologies (hazard ratio, HR:
0.58, P = 0.005) in our cohort. This might be due to compliance in terms of alcohol abstinence after a significant event such as variceal bleeding in contrast to ongoing liver injury with other aetiologies.
Although univariate analysis demonstrated a highly significant positive impact of an additional NSBB intake in secondary prophylaxis compared (HR: 0.58, P<0.001) to EBL only, this beneficial effect of NSBB was not observed on multivariate analysis (HR: 0.83, P = 0.244). However, given the impressive difference in early mortality within 6 months after EBL, we confirmed that NSBB intake was associated with a 42% risk reduction (HR 0.53, P = 0.008) of 6-months mortality. In competing risk analysis, there was again an overall reduction in mortality risk by 50% with NSBB + EBL combination over EBL monotherapy. In the subgroup of compensated patients, NSBB addition did not decrease the risk for further decompensation in compensation patients without ascites.
The development of ascites is known to indicate a decompensated state with a significant risk for mortality. 42 Similar to previous studies, we found that higher Child-Pugh score and the presence of severe/refractory ascites had a significant impact on rebleeding and mortality. Given the recent debate on the safety of NSBB therapy in patients with refractory ascites [43] [44] [45] we assessed the effects of NSBB therapy in subgroups with compensated and decompensated cirrhosis separately. Interestingly, the considerable reduction of 6-month mortality with NSBB + EBL combination vs EBL monotherapy was most pronounced in patients without severe/refractory ascites (HR: 0.37, P = 0.001), while in patients with severe/refractory ascites, NSBB addition to EBL did not have an independent beneficial effect on survival within the first 6 months (HR: 0.80, P = 0.567). This suggests that NSBB combination right from the start of secondary prophylaxis and prior to the development of severe/refractory ascites is most beneficial in terms of a mortality risk reduction.
The best strategy for patients with intolerance or contraindications to NSBBs or nonresponsive to NSBBs remains unknown. Given the inferior survival with EBL alone, our study underlines the importance of exploring alternative treatment strategies for secondary prophylaxis in patients who cannot be treated with NSBB, a scenario where transjugular intrahepatic portosystemic stents (TIPS) might represent a promising treatment option. 46, 47 The most important limitation of this study is its retrospective design and the fact that the treatment strategy was decided by the individual physician-considering there are endoscopists, gastroenterologists and hepatologists involved. Groups were not randomised and clinical visits during and after EBL sessions did not follow a regular pre-defined schedule, however, our observed bleeding and rebleeding rates in primary [6] [7] [8] and secondary prophylaxis 24, 26, 48 are in line with the literature. [6] [7] [8] 24, 26, 48 Importantly, patient groups treated with EBL monotherapy and EBL + NSBB combination therapy were comparable in their clinical characteristics.
This large real-life study shows that even in large tertiary care liver units Baveno recommendations are not followed in a significant proportion of patients. However, the current recommendations are fully supported by the observed results:
In primary prophylaxis, the combination of EBL with NSBBs did not reduce bleeding rates nor reduced mortality, but likely represents an overtreatment associated with unnecessary side effects. If NSBB monotherapy for primary prophylaxis is chosen the evaluation of haemodynamic response should be evaluated, since hepatic venous pressure gradient (HVPG) responders seem to have a favourable long-term outcome and survival. 10, 29, 37, 49 In secondary prophylaxis, the addition of NSBBs to EBL represents a crucial component of medical treatment, since EBL + NSBB combination therapy improves survival as compared to EBL monotherapy.
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